99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy?
- 1 February 2003
- journal article
- clinical trial
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (2) , 193-196
- https://doi.org/10.1007/s00259-002-1030-z
Abstract
Several years ago technetium-99m tetrofosmin was reported to localise parathyroid adenomas. The aim of this study was to compare the sensitivity of this radiopharmaceutical with that of 99mTc-sestamibi using a double-phase parathyroid scintigraphy protocol. Scans of 12 patients were evaluated visually and lesion to thyroid ratios were calculated. Nine of the patients were subsequently operated on; a total of eight parathyroid adenomas or hyperplastic glands were histologically confirmed in seven of the patients, while in one patient a parathyroid carcinoma was histologically proven. All of these patients had positive 99mTc-sestamibi scintigrams, whereas only two 99mTc-tetrofosmin scintigrams were positive. With 99mTc-sestamibi there was a significant increase in the lesion to thyroid ratio from 10 min to 90 min and 150 min p.i. which was not seen on scintigraphy with 99mTc-tetrofosmin. This makes 99mTc-tetrofosmin less suitable for double-phase parathyroid scintigraphy.Keywords
This publication has 0 references indexed in Scilit: